California Assembly considers multiple bills on pharmacy regulation and health care access

California's State Board of Pharmacy convened on June 20, 2025, to discuss several significant legislative measures aimed at enhancing public health and pharmacy practices. Among the key topics was Assembly Bill 529, which seeks to extend the board's authority to waive certain pharmacy law provisions for up to 120 days following a declared emergency. The board expressed its support for this measure, which is set for consideration by the Senate Appropriations Committee on June 23.

Another notable discussion centered on Assembly Bill 669, which aims to ensure a minimum of 28 days of treatment for substance use disorders and eliminate prior authorization requirements for FDA-approved addiction medications deemed necessary by healthcare providers. This bill is scheduled for review by the Senate committee on rules, with the board also establishing a support position.

Assembly Bill 957, which would prohibit pharmacies from selling cigarettes and tobacco products, was also on the agenda. The board reaffirmed its support for this measure, which aligns with its policy goals and is expected to be considered by the Senate Business Professions and Economic Development Committee on June 30.

The board also reviewed Assembly Bill 968, allowing pharmacists to furnish a 12-month supply of FDA-approved contraceptives at a patient's request. This bill, which has been amended to include both hormonal and non-hormonal contraceptives, is scheduled for discussion in the Senate Business and Economic Development Committee.

Assembly Bill 1460, which addresses discriminatory practices by prescription drug manufacturers, was highlighted for its potential to protect underserved communities by ensuring equitable access to medications. The board's support for this measure reflects its commitment to addressing healthcare disparities.

Additionally, Assembly Bill 1503, the board's sunset measure, aims to extend its operations until January 1, 2030, and includes provisions for establishing a pharmacy technician advisory committee. This bill is also set for consideration by the Senate Business Professions and Economic Development Committee.

The meeting concluded with discussions on Senate Bill 40, which would prohibit health insurers from imposing step therapy for insulin coverage, and Senate Bill 41, which seeks to regulate pharmacy benefits managers (PBMs) to enhance transparency and protect patient access to medications.

Overall, the board's discussions reflect a proactive approach to improving healthcare access and pharmacy practices in California, with several measures poised for legislative advancement in the coming weeks.